loading...| Preferred Name |
crizotinib |
|
| Synonyms |
c-met/HGFR tyrosine kinase inhibitor PF-02341066 |
|
| Definitions |
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C74061" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74061" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000586080 |
|
| altLabel |
c-met/HGFR tyrosine kinase inhibitor PF-02341066 PF-2341066 Xalkori PF-02341066 MET Tyrosine Kinase Inhibitor PF-02341066 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4- yl)pyridin-2-amine c-met/hepatocyte growth factor receptor tyrosine kinase inhibitor PF-02341066 2-Pyridinamine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H- pyrazol-4-yl] |
|
| CAS Registry |
877399-52-5 |
|
| cui |
C3204573 C1957666 C2974289 |
|
| DATE FIRST PUBLISHED |
2008-01-22 |
|
| Date last modified |
2015-10-10 |
|
| definition |
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C74061" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74061" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C74061 |
|
| notation |
CDR0000586080 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
crizotinib |
|
| tui |
T109 T121 |